Michael Porter’s Five Forces model is a strategic framework used to study the global women’s health market. Strategic business managers seeking to gain a competitive advantage in the women’s health market can utilize this model to better understand the industry structure, competitive pressures, and profitability dynamics in which firms operate. The components of each force and the degree of impact of each component have been broken down and analyzed in the context of the global women’s health market.
PORTER'S FIVE FORCES Analysis: global Womens health market
Threat of New Entrants
The threat of new entrants in the women’s health market is moderate to low due to stringent regulatory requirements and high R&D costs. Agencies such as the U.S. Food and Drug Administration and European Medicines Agency impose strict clinical trial and safety standards for products like oral contraceptives, fertility injectables, and hormone replacement therapies. Additionally, developing products such as intrauterine devices (IUDs) or bisphosphonates requires significant technological expertise and long approval timelines. However, the rise of digital health and over-the-counter products like lubricants and vaginal moisturizers has slightly lowered entry barriers for smaller players. Government initiatives promoting reproductive health access also encourage innovation, but compliance costs and patent protections continue to limit widespread new market entry.
Bargaining Power of Suppliers
Supplier power is moderate, influenced by the availability of raw materials, active pharmaceutical ingredients (APIs), and specialized manufacturing capabilities. For complex drugs such as fertility injectables and hormone therapies, suppliers with high-quality API production capabilities hold greater influence. Regulatory bodies like the World Health Organization emphasize quality assurance and Good Manufacturing Practices, which restrict supplier options to certified vendors. However, large pharmaceutical companies often maintain diversified supply chains, reducing dependency on single suppliers. In contrast, products like vaginal lubricants and moisturizers rely on more commoditized inputs, lowering supplier power. Global supply disruptions, as observed during pandemics, can temporarily increase supplier leverage, particularly for hormone-based and biologic treatments.
Bargaining Power of Buyers
Buyer power in this market is moderate to high, driven by increasing awareness, accessibility, and healthcare policy support. Patients, healthcare providers, and public health systems influence demand for contraceptives, fertility treatments, and menopause-related therapies. Organizations such as the World Health Organization and United Nations Population Fund promote access to affordable reproductive health products, strengthening buyer influence, particularly in price-sensitive regions. Government procurement programs and insurance coverage further enhance bargaining power by negotiating lower prices for essential medicines. Additionally, the availability of alternative treatment options, including generics and non-hormonal products, allows consumers to switch easily, increasing price sensitivity and demand for safer, more effective, and affordable solutions.
Threat of Substitutes
The threat of substitutes is moderate, as multiple treatment alternatives exist across product categories. For example, hormonal contraceptives can be substituted with non-hormonal methods such as copper IUDs or barrier methods. Similarly, fertility drugs may be complemented or replaced by assisted reproductive technologies (ART), while hormone replacement therapy (HRT) faces competition from lifestyle interventions and non-hormonal therapies. According to guidance from the National Institutes of Health, patients increasingly explore alternative treatments due to concerns about side effects and long-term safety. In vaginal health, over-the-counter lubricants and natural products act as substitutes for prescription therapies. This wide range of alternatives limits pricing power and encourages continuous innovation among manufacturers.
Intensity of Rivalry
Competitive rivalry in the global women’s health market is high, driven by the presence of established pharmaceutical and healthcare companies competing across multiple segments. Companies such as Pfizer Inc., Bayer AG, and Merck & Co., Inc. invest heavily in R&D, clinical trials, and product differentiation. The market is characterized by frequent product launches, generic competition, and strategic collaborations to expand portfolios in contraceptives, fertility drugs, and menopause therapies. Additionally, government health programs and global organizations push for affordability and accessibility, intensifying price competition. Rapid advancements in femtech, personalized medicine, and digital health solutions further increase rivalry, compelling companies to innovate continuously and improve patient outcomes.
Product Pipeline Analysis
Product pipeline
Drug Candidate
Company
Development Stage
Mechanism of Action
Elinzanetant (Lynkuet®)
Bayer AG
FDA Approved / Launching (2025-2026)
Non-hormonal dual neurokinin-1 and 3 (NK1,3) receptor antagonist for menopause symptoms.
FOR-6219 (OG-6219)
Organon (via Forendo)
Phase 2
HSD17B1 enzyme inhibitor; selectively reduces local estrogen in lesions without suppressing systemic levels.
Ovaprene®
Daré Bioscience
Phase 3 (Pivotal)
Monthly, non-hormonal intravaginal ring that creates a physical and chemical barrier to sperm.
FemBloc®
Femasys Inc.
Phase 3 (Pivotal - U.S. FINALE trial)
Non-surgical permanent birth control; uses a biopolymer to occlude the fallopian tubes.
DARE-HPV
Daré Bioscience
Phase 2 (Commencing 2026)
Therapeutic cream for high-risk Human Papillomavirus (HPV) infection (under ARPA-H contract).
HMI-115
Hope Medicine
Phase 2
First-in-class monoclonal antibody that blocks the prolactin receptor to treat endometriosis.
Merigolix (TU2670)
TiumBio
Phase 2a (Topline results reported)
Oral gonadotropin-releasing hormone (GnRH) receptor antagonist for endometriosis pain.
Linzagolix
Kissei Pharmaceutical
Phase 3 / Regulatory Review
Oral GnRH receptor antagonist for uterine fibroids and endometriosis.
BAY2395840
Bayer AG
Phase 1
Targeted treatment for endometriosis-associated pain.
DARE-PTB1
Daré Bioscience
Phase 1/2
Bio-identical progesterone intravaginal ring designed to reduce the risk of preterm birth.
Case Study Analysis
1. Contraceptives: Diversification and Long-Acting Solutions
The market for contraceptives is shifting from daily oral medications to Long-Acting Reversible Contraceptives (LARCs), which offer multi-year protection.
Bayer AG: As a leader in the IUD space, Bayer's Mirena® and LNG-IUS systems are central to its strategy. To meet global demand, Bayer announced an investment of over €400 million in 2021 to expand production facilities in Finland and Costa Rica, specifically for LARCs. These sites utilize automation and robotics to scale the production of hormonal implants and intrauterine systems.
Organon: Since its spin-off from Merck in 2021, Organon has anchored its portfolio with Nexplanon® (etonogestrel implant). In 2024, the company submitted an application to the FDA for a five-year duration of use for Nexplanon, which could extend its market exclusivity in the U.S. if approved.
2. Fertility and Ovulation: Precision and Portfolio Growth
Growth in this segment is driven by advancements in injectables and oral medications for ovulation induction.
Organon’s Fertility Portfolio: In the third quarter of 2024, Organon reported a 14% increase (excluding foreign exchange) in its fertility business, fueled by higher demand in the United States and new launches in international markets. Key brands include Follistim AQ and Elonva™.
3.
